Kemi Olugemo, MD, MPH, serves as the Chief Medical Officer at KORRO BIO INC, a biotechnology company focused on developing RNA editing therapeutics. Dr. Olugemo brings a wealth of experience in clinical development and medical affairs to her role, having previously held leadership positions at several prominent biopharmaceutical companies. She earned her medical degree from the University of Ilorin in Nigeria and completed her Master of Public Health at the University of Alabama at Birmingham. Her diverse background in both medicine and public health has equipped her with a unique perspective on healthcare and drug development. Throughout her career, Dr. Olugemo has been instrumental in advancing clinical programs across various therapeutic areas, including rare diseases, oncology, and neurology. Prior to joining KORRO BIO, she served as the Vice President of Clinical Development at a leading gene therapy company, where she played a key role in designing and executing clinical trials that led to successful regulatory submissions. Her strategic vision and commitment to patient-centric care have been recognized through numerous awards and accolades, including being named one of the "Top 100 Healthcare Leaders" by a renowned industry publication. As Chief Medical Officer at KORRO BIO, Dr. Olugemo is responsible for overseeing the company's clinical development strategy and ensuring the successful translation of its RNA editing platform into transformative therapies for patients. She works closely with cross-functional teams to design and implement clinical trials that prioritize patient safety and efficacy. Under her leadership, KORRO BIO aims to revolutionize the treatment landscape for genetic diseases by harnessing the power of RNA editing to address the underlying causes of these conditions. Dr. Olugemo's passion for innovation and her dedication to improving patient outcomes make her an invaluable asset to the company and the broader biopharmaceutical community.